Abstract: Disclosed is an in vitro method for the identification and the concomitant monitoring of the therapy and cure of drug-induced or addictive substance-induced liver damage, in which the occurrence of the human enzyme carbamoyl synthase 1 (CPS 1) or its concentration is determined in serum or plasma samples from patients who are being or have been treated with potentially liver-damaging drugs, or from people who take harmful stimulants and addictive substances or are exposed to hepatotoxic substances.
Type:
Application
Filed:
May 8, 2007
Publication date:
July 9, 2009
Applicant:
B.R.A.H.M.S Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Nils G. Morgenthaler
Abstract: An in vitro method for the detection, determination of severity and monitoring and prognosis of neurodegenerative diseases is disclosed. The presence and/or concentration of the physiologically inactive proadrenomedullin (proADM) partial peptide, in particular, the midregional proADM partial peptide, is determined in a biological fluid of a patient who is suffering from a neurodegenerative disease or is suspected of having such a disease. Conclusions about the presence, course, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the presence and/or concentration of the specific partial peptide in the biological sample.
Type:
Grant
Filed:
July 24, 2006
Date of Patent:
June 16, 2009
Assignee:
B.R.A.H.M.S. Aktiengesellschaft
Inventors:
Andreas Bergmann, Andrea Ernst, Harald Hampel
Abstract: The present invention relates to the use of short-chain SRL alcohol dehydrogenase (DHRS4, SEQ ID NO: 1) and peptides thereof as humoral biomarkers for the diagnostic detection and prognosis of the course, and also monitoring the course and therapy of septic inflammations and infections.
Type:
Application
Filed:
March 6, 2006
Publication date:
May 28, 2009
Applicant:
B.R.A.H.M.S AKTIENGESELLSCHAFT
Inventors:
Andreas Bergmann, Joachim Struck, Monika Uhlein
Abstract: The invention relates to a method for the early differential diagnosis and detection, prognosis and determination of the degree of severity of a case of sepsis and systemic infections similar to sepsis and also for the determination of the course of infection during therapy. The above is achieved, whereby the amount of CA 125 in a biological fluid from a patient is determined, preferably with determination of at least one further parameter suitable for diagnosis of sepsis, for a patient who has sepsis or is suspected of having sepsis and, from the determined amounts of CA 125 conclusions are drawn as to the presence, expected course, the degree and/or the success of measures taken for the therapy of sepsis.
Abstract: Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.
Type:
Grant
Filed:
March 25, 2004
Date of Patent:
March 3, 2009
Assignee:
B.R.A.H.M.S. Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Wolfgang Weglöhner
Abstract: The present invention relates to a method for the early determination of the risk of mortality of patients in intensive care units or emergency care units during which the concentration of Cu/Zn superoxide dismutase (Cu/Zn SOD) in a serum sample or plasma sample of the patient is selectively determined, and quantitatively or semi-quantitatively measured concentrations, which exceed a predetermined threshold value are correlated with a high risk of mortality.
Type:
Application
Filed:
February 2, 2005
Publication date:
January 8, 2009
Applicant:
B.R.A.H.M.S AKTIENGESELLSCHAFT
Inventors:
Andreas Bergmann, Joachim Struck, Monika Uhlein, Nils G. Morgenthaler
Abstract: Monoclonal antibodies (mAbs) having thyroid stimulating activity (TSAb), especially full or considerably agonistic activity, or thyroid blocking activity (TBAb), which are obtainable by genetic immunization of mice, or fragments (F(ab?)2, Fab or Fv) or humanized forms of such monoclonal antibodies or single chain forms (SCA; scFv) of such fragments, which antibodies, or their fragments, compete with bovine TSH for epitopes of the human TSHr, compete with autoantibodies from sera from Graves' patients as well as with autoantibodies from sera from patients harboring blocking autoantibodies for epitopes of the human TSHr, bind to conformational epitopes of the human TSHr located in the first 281 amino acids of the human TSHr, and usually also bind to TSFR receptors (TSHr) from different animals. Various uses of such antibodies, or of peptides corresponding to variable regions of such antibodies, are also described and claimed.
Type:
Application
Filed:
June 16, 2005
Publication date:
January 8, 2009
Applicant:
B.R.A.H.M.S AKTIENGESELLSCHAFT
Inventors:
Andreas Bergmann, Nils G. Morgenthaler, Gilbert Vassart, Sabine Costagliola
Abstract: The invention relates to the diagnosis of disease based on the presence of biochemical components in human or animal body fluids, tissues and/or biomaterials.
Abstract: Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined.
Type:
Application
Filed:
March 3, 2008
Publication date:
October 9, 2008
Applicant:
B.R.A.H.M.S. Aktiengesellschaft
Inventors:
Andreas BERGMANN, Christina Fischer-Schulz, Joachim Struck
Abstract: The invention relates to the use of Asialo-Gm1 (Agm1,) and/or GM gangliosides, and substances which simulate the carbohydrate part of said gangliosides in terms of binding to anti-AGm1 antibodies and/or anti-Gm1 antibodies, for producing an agent which blocks or binds to anti-AGm1 antibodies and/or anti-Gm1 antibodies which bind to natural killer cells (NKC), said agent being administered to patients at high risk of sepsis and to patients with sepsis, in whom such antibodies have been detected, for the prevention, inhibition and treatment of sepsis.
Abstract: CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are drawn from a measured PCT immunoreactivity which is above a threshold value typical for healthy individuals.
Type:
Application
Filed:
July 19, 2006
Publication date:
August 28, 2008
Applicant:
B.R.A.H.M.S AKTIENGESELLSCHAFT
Inventors:
Andreas Bergmann, Andrea Ernst, Harald Hampel
Abstract: An in vitro method for the detection, determination of severity and monitoring and prognosis of neurodegenerative diseases is disclosed. The presence and/or concentration of the physiologically inactive proadrenomedullin (proADM) partial peptide, in particular, the midregional proADM partial peptide, is determined in a biological fluid of a patient who is suffering from a neurodegenerative disease or is suspected of having such a disease. Conclusions about the presence, course, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the presence and/or concentration of the specific partial peptide in the biological sample.
Type:
Application
Filed:
July 24, 2006
Publication date:
August 21, 2008
Applicant:
B.R.A.H.M.S AKTIENGESELLSCHAFT
Inventors:
Andreas Bergmann, Andrea Ernst, Harald Hampel
Abstract: Use of carbamoyl phosphate synthetase 1 (CPS 1) and/or of fragments of the N-terminal part of CPS 1 from body fluids or body tissues as marker peptides for the diagnosis and for the prognosis and the monitoring of inflammations and infections, including sepsis, and of liver failure as part of multiorgan failure or for determinations in connection with inflammatory and other liver diseases.
Type:
Grant
Filed:
April 15, 2003
Date of Patent:
August 19, 2008
Assignee:
B.R.A.H.M.S. Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Monika Uhlein
Abstract: Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined.
Type:
Grant
Filed:
April 15, 2003
Date of Patent:
July 29, 2008
Assignee:
B.R.A.H.M.S. Aktiengesellschaft
Inventors:
Andreas Bergmann, Christina Fischer-Schulz, Joachim Struck
Abstract: Use of carbamoyl phosphate synthetase 1 (CPS 1) and/or of fragments of the N-terminal part of CPS 1 from body fluids or body tissues as marker peptides for the diagnosis and for the prognosis and the monitoring of inflammations and infections, including sepsis, and of liver failure as part of multiorgan failure or for determinations in connection with inflammatory and other liver diseases.
Type:
Application
Filed:
February 29, 2008
Publication date:
July 24, 2008
Applicant:
B.R.A.H.M.S. Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Monika Uhlein
Abstract: Methods for diagnosis, early diagnosis, differential diagnosis, assessment of the severity and therapy-accompanying monitoring and prognosis of chronically inflammatory intestinal diseases (Crohn's disease, Colitis ulcerosa), in which the presence and/or the amount of one or more antibodies which bind to ribosomal proteins, in particular P0 and L5, are determined in the serum, plasma, tissue samples and/or stool of a patient who is suffering from a chronically inflammatory intestinal disease or in whom such a disease is suspected. The blocking or removal of such antibodies and/or the influencing of antigen-presenting cells or specifically reactive T-cells which react to ribosomal proteins, such as P0 and L5, by suitable agents can be therapeutically utilized.
Type:
Grant
Filed:
September 3, 2002
Date of Patent:
April 15, 2008
Assignee:
B.R.A.H.M.S Aktiengesellschaft
Inventors:
Andreas Bergmann, Marita Willnich, Detlef Schuppan
Abstract: Use of calcineurin B homologous protein (CHP) from body fluids or body tissues as a marker peptide for diagnosis, for prognosis and for monitoring the course of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.
Type:
Grant
Filed:
June 17, 2002
Date of Patent:
June 26, 2007
Assignee:
B.R.A.H.M.S Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Monika Ühlein
Abstract: Uses of aldose 1-epimerase (SEQ ID NO:3) from body fluids or body tissues in human and veterinary medicine as a marker peptide for diagnosis, for prognosis of the course and for monitoring of the course of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.
Type:
Grant
Filed:
November 29, 2002
Date of Patent:
January 2, 2007
Assignee:
B.R.A.H.M.S Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Monika Ühlein
Abstract: The invention relates to novel peptides and partial peptide sequences for the diagnosis and therapy of inflammations and sepsis, which are formed in the case of inflammations and/or infections of primates and humans, and their use or the use of antibodies formed against these peptides in diagnosis and therapy.
Type:
Grant
Filed:
April 16, 2002
Date of Patent:
December 26, 2006
Assignee:
B.R.A.H.M.S. Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Monika Ühlein
Abstract: Use of carbamoyl phosphate synthetase 1 (CPS 1) and/or of fragments of the N-terminal part of CPS 1 from body fluids or body tissues as marker peptides for the diagnosis and for the prognosis and the monitoring of inflammations and infections, including sepsis, and of liver failure as part of multiorgan failure or for determinations in connection with inflammatory and other liver diseases.
Type:
Application
Filed:
April 15, 2003
Publication date:
June 1, 2006
Applicant:
B.R.A.H.M.S Aktiengesellschaft
Inventors:
Andreas Bergmann, Joachim Struck, Monika Uhlein